Figure 1

a

b

c

d

e

f

FAP score negative
FAP score low
FAP score high

Log rank
P=0.002
HR 4.17 (1.65-10.6)

Log rank
P=0.017
HR 1.89 (1.14-3.15)
Figure 2

(a) Disease-Free Survival Proportion (%)
- N negative
  - n=54
- N positive
  - n=40

Log rank
P<0.001
HR 4.97 (1.94-12.7)
(n=94)

(b) Overall Survival Proportion (%)
- N negative
  - n=54
- N positive
  - n=40

Log rank
P<0.001
HR 3.86 (1.89-7.89)
(n=94)

(c) Proportion of patients
- N negative
- N positive

(d) FAP score
- n=54
- n=40

P<0.0001

(e) Number of LN metastasis
- FAP score

R=0.448 (P<0.0001)
Figure 3

(a) Western blot analysis showing expression of SMA, FAP, Vimentin, and β-actin in CM/TE1, CM/TE4, and CM/OE19 conditions.

(b) Microscopy images showing cell morphology in TE1, TE4, and OE19 conditions with and without CM/CAF treatment.

(c) Quantitative analysis of cell morphology showing significant differences between control and CM/CAF treated samples for TE1, TE4, and OE19.

(d) Additional quantitative analysis for control and CM/CAF treated samples showing significant differences.

(e) Western blot analysis of MMP2 and β-actin in TE1, TE4, and OE19 conditions after co-culture with FEF3.
Figure 4

(a) Images of mice showing TE4 and Co-culture TE4+FEF3 at 1 week, 2 weeks, 3 weeks, 4 weeks, and 5 weeks.

(b) Luminescence intensity (photons/sec) graph showing TE4 (n=5) and TE4+FEF3 (n=5).

(c) Box plot comparing Luminescence intensity (photons/sec) for TE4 and TE4+FEF3.

(d) HE and SMA staining of TE4 and Co-culture TE4+FEF3.

(e) Images showing lymph node, liver, and peritoneal metastasis.

(f) Bar graph showing metastatic incidence in lymph node, liver, and peritoneal with P<0.01.

(g) Images showing liver, esophagus, stomach, and tumor.

(h) Box plot comparing the number of metastatic lymph nodes for TE4 and TE4+FEF3 with P<0.01.